Trial Profile

A Phase 1b/2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Prizloncabtagene autoleucel (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions
Sponsors AbelZeta Pharma; Cellular Biomedicine Group; Janssen Research & Development

Most Recent Events

28 Jul 2025 Planned number of patients changed from 230 to 385.
28 Jul 2025 Planned primary completion date changed from 29 May 2026 to 29 Dec 2028.
20 Jun 2025 According to Johnson & Johnson media release, the global clinical study data from this trial will be presented at the 2025 International Conference on Malignant Lymphoma from June 17-21.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com